Cargando…

Effects of matrix on plasma levels of EPA and DHA in dogs

EPA and DHA are often used in veterinary medicine due to their beneficial effects for several medical conditions such as osteoarthritis. EPA and DHA are administered to dogs through different matrices. The aim of the present study was to determine the effects on the plasma levels in dogs caused by v...

Descripción completa

Detalles Bibliográficos
Autores principales: Goffin, Kay, van Maris, Marc, Corbee, Ronald J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672307/
https://www.ncbi.nlm.nih.gov/pubmed/29152241
http://dx.doi.org/10.1017/jns.2017.30
_version_ 1783276405678669824
author Goffin, Kay
van Maris, Marc
Corbee, Ronald J.
author_facet Goffin, Kay
van Maris, Marc
Corbee, Ronald J.
author_sort Goffin, Kay
collection PubMed
description EPA and DHA are often used in veterinary medicine due to their beneficial effects for several medical conditions such as osteoarthritis. EPA and DHA are administered to dogs through different matrices. The aim of the present study was to determine the effects on the plasma levels in dogs caused by various matrices for EPA and DHA administration. In this study, three different n-3 PUFA formulations were used: soft chew tablet (CCx); liquid fish oil (LFO); and enriched kibbles (EK). The formulations were administered single-dose and compared in a randomised, cross-over designed study with a 1-week wash-out period. Several variables were observed after the administration of these formulations in thirteen dogs: the NEFA plasma concentration, the AUC for 1 d (AUC0–24 h), and maximum plasma concentration for both EPA and DHA. All plasma fatty acid levels reached baseline levels within 72 h. CCx (median = 2·987) had a significantly lower AUC0–24 h for EPA compared with LFO (median = 5·647, P = 0·043) and EK (median = 5·119, P = 0·032) (F(2,22) = 4·637, P = 0·021). CCx (median = 2·471) AUC0–24 h for DHA was significantly lower compared with LFO (median = 4·837, Z = −2·56, P = 0·011) and EK (median = 4·413, Z = −2·59, P = 0·01). EPA and DHA plasma levels were affected by matrix, as with the CCx, the AUC0–24 h of EPA and DHA were both lower compared with LFO and EK. The effect of matrix on bioavailability is important for product development as well as for clinical trials studying effects of EPA and DHA.
format Online
Article
Text
id pubmed-5672307
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-56723072017-11-16 Effects of matrix on plasma levels of EPA and DHA in dogs Goffin, Kay van Maris, Marc Corbee, Ronald J. J Nutr Sci Research Article EPA and DHA are often used in veterinary medicine due to their beneficial effects for several medical conditions such as osteoarthritis. EPA and DHA are administered to dogs through different matrices. The aim of the present study was to determine the effects on the plasma levels in dogs caused by various matrices for EPA and DHA administration. In this study, three different n-3 PUFA formulations were used: soft chew tablet (CCx); liquid fish oil (LFO); and enriched kibbles (EK). The formulations were administered single-dose and compared in a randomised, cross-over designed study with a 1-week wash-out period. Several variables were observed after the administration of these formulations in thirteen dogs: the NEFA plasma concentration, the AUC for 1 d (AUC0–24 h), and maximum plasma concentration for both EPA and DHA. All plasma fatty acid levels reached baseline levels within 72 h. CCx (median = 2·987) had a significantly lower AUC0–24 h for EPA compared with LFO (median = 5·647, P = 0·043) and EK (median = 5·119, P = 0·032) (F(2,22) = 4·637, P = 0·021). CCx (median = 2·471) AUC0–24 h for DHA was significantly lower compared with LFO (median = 4·837, Z = −2·56, P = 0·011) and EK (median = 4·413, Z = −2·59, P = 0·01). EPA and DHA plasma levels were affected by matrix, as with the CCx, the AUC0–24 h of EPA and DHA were both lower compared with LFO and EK. The effect of matrix on bioavailability is important for product development as well as for clinical trials studying effects of EPA and DHA. Cambridge University Press 2017-07-24 /pmc/articles/PMC5672307/ /pubmed/29152241 http://dx.doi.org/10.1017/jns.2017.30 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Goffin, Kay
van Maris, Marc
Corbee, Ronald J.
Effects of matrix on plasma levels of EPA and DHA in dogs
title Effects of matrix on plasma levels of EPA and DHA in dogs
title_full Effects of matrix on plasma levels of EPA and DHA in dogs
title_fullStr Effects of matrix on plasma levels of EPA and DHA in dogs
title_full_unstemmed Effects of matrix on plasma levels of EPA and DHA in dogs
title_short Effects of matrix on plasma levels of EPA and DHA in dogs
title_sort effects of matrix on plasma levels of epa and dha in dogs
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672307/
https://www.ncbi.nlm.nih.gov/pubmed/29152241
http://dx.doi.org/10.1017/jns.2017.30
work_keys_str_mv AT goffinkay effectsofmatrixonplasmalevelsofepaanddhaindogs
AT vanmarismarc effectsofmatrixonplasmalevelsofepaanddhaindogs
AT corbeeronaldj effectsofmatrixonplasmalevelsofepaanddhaindogs